Skip to main
  1. Stocks
  2. Vera Therapeutics
  3. Forecast
VERA

Vera Therapeutics (VERA) Stock Forecast & Price Target

Vera Therapeutics (VERA) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 30%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Vera Therapeutics is well positioned by Trutakna’s unexpectedly strong early launch, with $10.3M in 3Q26 net sales versus $4.0M consensus and about 700 patient start forms since July 7, indicating accelerating real-world demand in a large IgAN market. Its fundamental case is reinforced by ORIGIN 3 data showing a 5.00 mL/min/1.73 m²/yr eGFR slope advantage, 5.1% versus 17.8% kidney-disease progression, and no dialysis, transplant, or death events on Trutakna, supporting the sBLA and potential full approval by mid-2027. With approximately $384M in cash, cash equivalents, and marketable securities at the end of 3Q26, plus a pathway to 50% covered lives by year-end, the company appears financially capable of funding commercialization while converting early launch momentum into durable revenue.

Bears say

Vera Therapeutics is facing a negative setup because Trutakna’s early $10M first-quarter revenue and 700 patient start forms still leave commercial traction difficult to gauge, while another IgAN competitor could launch in December and pressure uptake. The company also expects higher cost of goods sold at 15%-20% from 4Q26 onward due to royalty payments to Merck KGaA, which could weigh on margins as R&D and SG&A remain elevated. Although it ended 3Q 2026 with $384M in cash and later drew $75M, it is not expected to be profitable until 2029 and may need additional capital, creating dilution risk.

Vera Therapeutics (VERA) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 30% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vera Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Vera Therapeutics (VERA) Analyst Forecast & Price Prediction

Get the latest Vera Therapeutics (VERA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Vera Therapeutics (VERA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vera Therapeutics (VERA) Forecast

Analysts have given Vera Therapeutics (VERA) a Buy based on their latest research and market trends.

According to 10 analysts, Vera Therapeutics (VERA) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $70.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $70.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vera Therapeutics (VERA)


Vera Therapeutics (VERA) Analyst Forecast & Price Prediction

Get the latest Vera Therapeutics (VERA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Vera Therapeutics (VERA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover VERA stock data and trends